This article is more than 5 years old. Information may no longer be current.

FDA approves new drug application for TobraDex ST

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has approved Alcon's new drug application for a new formulation of a fixed combination of tobramycin and dexamethasone for treating inflammatory ocular conditions.

The application provides for the use of the drug, called TobraDex ST (tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05%), for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and for instances in which there is significant risk of superficial bacterial ocular infection, according to a letter from the FDA.

Currently, Alcon has not disclosed its plans to market the drug.